Table 3.

Completed and active trials primarily completed in 5 years of HDAC, VEGF, and EGFR related therapy.

Gene	Agent name	Glioma type	Clinical trials	Development phase	Status
HDAC	Vorinostat	DIPG	NCT01189266	Phase I/II	Active
		DIPG	NCT02420613	Phase I	Active
		HGG	NCT01236560	Phase II/III	Completed
		HGG, recurrent GBM	NCT01266031	Phase I/II	Completed
	Belinostat	GBM	NCT02137759	Phase II	Active
VEGF	Bevacizumab	Anaplastic glioma, recurrent GBM	NCT01836536	Unknown	Completed
		Recurrent ependymoma, WHO II, III glioma	NCT00381797	Phase II	Completed
		GBM	NCT01091792	Early phase I	Completed
		HGG, recurrent GBM	NCT01266031	Phase I/ II	Completed
		HGG	NCT01236560	Phase II/III	Completed
		Recurrent GBM	NCT01648348	Phase I/II	Completed
		GBM	NCT01498328	Phase II	Completed
		GBM, oligodendroglioma	NCT01609790	Phase II	Active
		Recurrent GBM	NCT02142803	Phase I	Active
		Recurrent GBM	NCT02974621	Phase II	Active
EGFR	Erlotinib	HGG	NCT01257594	Phase I	Completed
	Lapatinib	Recurrent HGG	NCT02101905	Phase I	Active
	Unknown†	GBM	NCT01454596	Phase I/II	Completed
	AMG 595	Recurrent GBM, AA	NCT01475006	Phase I	Completed
	Sym004	Recurrent GBM	NCT02540161	Phase II	Completed
	Depatux-M	GBM	NCT02343406	Phase II	Completed
		GBM	NCT02573324	Phase II/III	Active
		GBM	NCT03419403	Phase III	Terminated
		GBM	NCT01800695	Phase I	Completed
	Dacomitinib	Recurrent GBM	NCT01520870	Phase II	Completed
		GBM	NCT01112527	Phase II	Completed
	Tesevatinib	GBM	NCT02844439	Phase II	Completed
	Afatinib	GBM	NCT00977431	Phase I	Completed
	Cetuximab	GBM, anaplastic astrocytoma	NCT01238237	Phase I	Completed
	Rindopepimut	GBM	NCT01498328	Phase II	Completed
		GBM	NCT01480479	Phase III	Completed

DIPG, diffuse intrinsic pontine glioma; HGG, high-grade glioma; GBM, glioblastoma; AA, anaplastic astrocytoma. ^†Epidermal growth factor receptor (EGFRv) III; chimeric antigen receptor (CAR); transduced peripheral blood lymphocytes (PBL).